Research Group
Gastrointestinal and Other Cancers
Sponsor
Vanderbilt-Ingram Cancer Center
Status
Active, not recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT02794428
A clinical study of the efficacy of oral alpha-difluoromethylornithine (eflornithine or DFMO) in male and female subjects ages 30-60 with gastric premalignant lesions in two high risk regions of Latin America.
Intervention
Eflornithine, Eflornithine placebo
Condition
Gastric Cancer, Gastric Intestinal Metaplasia
Investigators
Doug Morgan, MD, Keith Wilson, MD